{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:10:29Z","timestamp":1770970229971,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1002\/jps.22018","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T22:09:07Z","timestamp":1260914947000},"page":"2886-2898","source":"Crossref","is-referenced-by-count":18,"title":["Species-Specific Interaction of HIV Protease Inhibitors With Accumulation of Cholyl-Glycylamido-Fluorescein (CGamF) in Sandwich-Cultured Hepatocytes"],"prefix":"10.1016","volume":"99","author":[{"given":"Zhi-Wei","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos","family":"Van Pelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Camus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Snoeys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Augustijns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Annaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.22018_bb0005","series-title":"Drug transport in the liver","article-title":"Drug transporters: Molecular characterization and role in drug disposition","author":"Annaert","year":"2007"},{"key":"10.1002\/jps.22018_bb0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process","volume":"48","author":"Huang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.22018_bb0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1146\/annurev.pharmtox.44.101802.121444","article-title":"Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs","volume":"45","author":"Shitara","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1002\/jps.22018_bb0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00210-008-0312-9","article-title":"Recent progresses in the experimental methods and evaluation strategies of transporter functions for the prediction of the pharmacokinetics in humans","volume":"377","author":"Kitamura","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1002\/jps.22018_bb0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/138920008784746337","article-title":"The challenges of dealing with promiscuous drug-metabolizing enzymes, receptors and transporters","volume":"9","author":"Ma","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1002\/jps.22018_bb0030","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/mol.59.3.627","article-title":"Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat","volume":"59","author":"Funk","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1002\/jps.22018_bb0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/toxsci\/kfg217","article-title":"Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats","volume":"76","author":"Kostrubsky","year":"2003","journal-title":"Toxicol Sci"},{"key":"10.1002\/jps.22018_bb0040","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1128\/AAC.01136-06","article-title":"Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients","volume":"51","author":"Marin-Niebla","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.22018_bb0045","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Na+\/ taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2.6.875","article-title":"Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction","volume":"2","author":"Martignoni","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1002\/jps.22018_bb0055","first-page":"G1153","article-title":"Primary active transport of organic anions on bile canalicular membrane in humans","volume":"276","author":"Niinuma","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1002\/jps.22018_bb0060","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0022-3565(24)35038-4","article-title":"Species differences in the transport activity for organic anions across the bile canalicular membrane","volume":"290","author":"Ishizuka","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.22018_bb0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.vascn.2005.08.003","article-title":"Use of canalicular membrane vesicles (CMVs) from rats, dogs, monkeys and humans to assess drug transport across the canalicular membrane","volume":"53","author":"Shilling","year":"2006","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1002\/jps.22018_bb0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejps.2008.06.008","article-title":"Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human","volume":"35","author":"Li","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.22018_bb0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/dmd.108.023234","article-title":"Absolute difference of hepatobiliary transporter multidrug resistance-associated protein (MRP2\/Mrp2) in liver tissues and isolated hepatocytes from rat, dog, monkey, and human","volume":"37","author":"Li","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.107.019620","article-title":"Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2\/Mrp2, ABCC2\/Abcc2)","volume":"36","author":"Zimmermann","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1021\/mp0501022","article-title":"Hepatobiliary disposition in primary cultures of dog and monkey hepatocytes","volume":"3","author":"Rose","year":"2006","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.22018_bb0090","first-page":"43","article-title":"Plasma membrane specialization and intracellular polarity of freshly isolated rat hepatocytes","volume":"26","author":"Groothuis","year":"1981","journal-title":"Eur J Cell Biol"},{"key":"10.1002\/jps.22018_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0169-409X(96)00418-8","article-title":"Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes","volume":"22","author":"LeCluyse","year":"1996","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.22018_bb0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1096\/fasebj.3.2.2914628","article-title":"Hepatocyte function and extracellular matrix geometry: Long-term culture in a sandwich configuration","volume":"3","author":"Dunn","year":"1989","journal-title":"FASEB J"},{"key":"10.1002\/jps.22018_bb0105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1097-4652(199812)177:4<553::AID-JCP6>3.0.CO;2-F","article-title":"Long-term expression of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix","volume":"177","author":"Gomez-Lechon","year":"1998","journal-title":"J Cell Physiol"},{"key":"10.1002\/jps.22018_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-2478(03)00162-7","article-title":"Requirement of 3D extracellular network for maintenance of mature hepatocyte morphology and suppression of alpha-fetoprotein synthesis in vitro","volume":"90","author":"Kudryavtseva","year":"2003","journal-title":"Immunol Lett"},{"key":"10.1002\/jps.22018_bb0115","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-9556(24)15299-3","article-title":"Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats","volume":"27","author":"Liu","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0120","first-page":"G12","article-title":"Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration","volume":"277","author":"Liu","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1002\/jps.22018_bb0125","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0022-3565(24)38310-7","article-title":"Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes","volume":"289","author":"Liu","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.22018_bb0130","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1124\/dmd.107.019398","article-title":"Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: Kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors","volume":"36","author":"Ye","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/mp0340136","article-title":"Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells","volume":"1","author":"Su","year":"2004","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.22018_bb0140","first-page":"1277","article-title":"P-glycoprotein-mediated in vitro biliary excretion in sandwich-cultured rat hepatocytes","volume":"29","author":"Annaert","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.22018_bb0145","series-title":"Isolated and cultured hepatocytes, edition","first-page":"1","article-title":"Methods for preparation of adult and fetal hepatocytes","author":"Guguen-Guillouzo","year":"1986"},{"key":"10.1002\/jps.22018_bb0150","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bjp.0703062","article-title":"Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions","volume":"129","author":"Bader","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1002\/jps.22018_bb0155","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1023\/B:PHAM.0000033018.97745.0d","article-title":"P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: Relevance to the hepatobiliary disposition of a model opioid peptide","volume":"21","author":"Hoffmaster","year":"2004","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22018_bb0160","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejps.2006.11.003","article-title":"Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes","volume":"30","author":"Jorgensen","year":"2007","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.22018_bb0165","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1023\/A:1011994831139","article-title":"Partial maintenance of taurocholate uptake by adult rat hepatocytes cultured in a collagen sandwich configuration","volume":"15","author":"Liu","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.22018_bb0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/jhep.2000.8539","article-title":"Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2","volume":"32","author":"Fattinger","year":"2000","journal-title":"Hepatology"},{"key":"10.1002\/jps.22018_bb0175","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/jpet.106.119073","article-title":"Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP\/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity","volume":"321","author":"Leslie","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.22018_bb0180","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/jpet.103.061614","article-title":"Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat","volume":"308","author":"Treiber","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jps.22018_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00232-005-7004-x","article-title":"Organic anion transporting polypeptides of the OATP\/SLCO superfamily: Identification of new members in nonmammalian species, comparative modeling and a potential transport mode","volume":"208","author":"Meier-Abt","year":"2005","journal-title":"J Membr Biol"},{"key":"10.1002\/jps.22018_bb0190","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/j.1440-1681.2007.04798.x","article-title":"OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation","volume":"34","author":"Zhang","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1002\/jps.22018_bb0195","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/QAD.0b013e328011d7c1","article-title":"Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia","volume":"21","author":"Rodriguez-Novoa","year":"2007","journal-title":"Aids"},{"key":"10.1002\/jps.22018_bb0200","doi-asserted-by":"crossref","first-page":"12671","DOI":"10.1073\/pnas.231140698","article-title":"Mechanism of indinavir-induced hyperbilirubinemia","volume":"98","author":"Zucker","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.22018_bb0205","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cbi.2004.08.008","article-title":"Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia","volume":"150","author":"Campbell","year":"2004","journal-title":"Chem Biol Interact"},{"key":"10.1002\/jps.22018_bb0210","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AAC.50.2.762-764.2006","article-title":"Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors","volume":"50","author":"Kempf","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.22018_bb0215","unstructured":"EMEA., Prezista, INN-Darunavir. The European Medicines Agency edition. http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/prezista\/H-707-PI-en.pdf."},{"key":"10.1002\/jps.22018_bb0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/QAI.0b013e3181359cfb","article-title":"Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3","volume":"46","author":"Molina","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1002\/jps.22018_bb0225","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1468-1293.2008.00690.x","article-title":"Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers","volume":"10","author":"Tomaka","year":"2009","journal-title":"HIV Med"},{"key":"10.1002\/jps.22018_bb0230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s15010-008-8010-6","article-title":"Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts","volume":"37","author":"Torti","year":"2009","journal-title":"Infection"},{"key":"10.1002\/jps.22018_bb0235","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","article-title":"Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy","volume":"337","author":"Gulick","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.22018_bb0240","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team","volume":"337","author":"Hammer","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.22018_bb0245","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915325934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915325934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T21:09:55Z","timestamp":1739480995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915325934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0022354915325934"],"URL":"https:\/\/doi.org\/10.1002\/jps.22018","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}